Our findings imply that the combination therapy of malignant CLL cells with RTX, CP and anti-Nrf2 siRNA is a novel and efficient therapeutic strategy that was capable of destroying malignant cells. The gene discussed is NFE2L2; the disease is B-cell chronic lymphocytic leukemia.